Skip to main content

MAIA Biotechnology, Inc.

MAIA
Exchange
NYSE
Industry
Pharmaceutical Preparations
SEC CIK
0001878313

In the last 90 days, MAIA Biotechnology, Inc. insiders filed 7 open-market purchases and 0 sales; 43 institutions reported holding it in 13F filings for Q3 2026, worth $14.2M in total; no superinvestor holds it.

Key figures

Market capClose on Nov 18, 2026
$80.3M
Insider buysLast 90 days, $552.3K in total
7
Insider sellsOpen market, last 90 days
0
13F holdersQ3 2026, +7 vs. previous quarter
43
13F valueReported value at the end of Q3 2026
$14.2M
Superinvestors holdingAt the end of Q3 2026
0

Price chart

From SEC filings, in USD.

Revenue, FY2025
–
No comparable prior period
Net income, FY2025
-$22.4M
No comparable prior period
Free cash flow, FY2025
–
No comparable prior period
Revenue, Q3 FY2026
–
No comparable prior period

Short interest

See short data

From FINRA, settlement date Oct 30, 2026.

Short interest
2.45M
Shares sold short
Change
−70.7K
−2.8% vs. previous
Days to cover
9.02
At average daily volume

Superinvestors holding MAIA, Q3 2026

Go to the superinvestors tab

No superinvestor reported holding MAIA at the end of Q3 2026.

Latest insider trades

See all insider trades

Open-market purchases and sales by MAIA Biotechnology, Inc. insiders from Form 4, newest first.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Nov 17, 2026 (view filing)4:07 PM ETNov 13-164 daysSmith StanDirectorPPurchase+100.0K$1.00+$100.0K+6.6%1.62M after2 lots
Nov 17, 2026 (view filing)4:05 PM ETNov 13-164 daysVitoc VladChief Executive OfficerPPurchase+100.0K$1.00+$100.0K+9.5%1.15M after2 lots
Sep 15, 2026 (view filing)6:33 AM ETSep 141 dayVitoc VladChief Executive OfficerPPurchase+73.0K$1.37+$100.0K+7.5%1.05M after
Sep 14, 2026 (view filing)9:03 AM ETSep 104 daysGuerrero RamiroDirectorPPurchase+37.6K$1.32+$49.5K+5.1%773.3K after
Sep 1, 2026 (view filing)4:16 PM ETAug 26-286 daysLateGuerrero RamiroDirectorPPurchase+133.8K$1.38+$184.1K+22.2%735.7K after3 lots
Aug 26, 2026 (view filing)7:56 AM ETAug 242 daysGuerrero RamiroDirectorPPurchase+1.79K$1.33+$2.39K+0.3%601.9K after
Aug 24, 2026 (view filing)4:09 PM ETAug 204 daysGuerrero RamiroDirectorPPurchase+11.9K$1.37+$16.3K+2.0%600.1K after
Jun 2, 2026 (view filing)Jun 11 dayVitoc VladChief Executive OfficerPPurchase+72.7K$1.39+$101.1K+8.0%976.1K after
Jun 2, 2026 (view filing)Jun 11 daySmith StanDirectorPPurchase+75.0K$1.34+$100.5K+5.2%1.52M after
Jun 2, 2026 (view filing)Jun 11 dayGryaznov SergeiChief Scientific OfficerPPurchase+2.00K$1.35+$2.70K+4.5%46.5K after

Top 10 13F holders, Q3 2026

See all 43 holders

The largest institutional positions in MAIA Biotechnology, Inc. at the end of Q3 2026; share changes are against Q2 2026.

Institutions holding MAIA in Q3 2026
InstitutionSharesValue% of portfolioChange in sharesAction
Solas Capital Management, LLC3,030,845$3.58M2.00%00.0%Unchanged
Vanguard Capital Management LLC2,413,270$2.85M0.00%00.0%Unchanged
Centric Wealth Management1,167,070$1.27M0.19%+370,347+46.5%Added
683 Capital Management, LLC1,066,666$1.26M0.12%00.0%Unchanged
Geode Capital Management, LLC584,401$689.8K0.00%+80,021+15.9%Added
Cable Car Capital LLC514,583$607.2K0.18%00.0%Unchanged
Bleichroeder LP500,000$590.0K0.06%00.0%Unchanged
Renaissance Technologies LLC399,100$470.9K0.00%−16,600−4.0%Reduced
BlackRock, Inc.394,772$465.8K0.00%−8,239−2.0%Reduced
Vanguard Fiduciary Trust Co336,688$397.3K0.00%00.0%Unchanged

Holders of 5% or more of MAIA

See all 2 holders and filings

Holders whose latest Schedule 13D or 13G filing reports 5% or more of MAIA Biotechnology, Inc..

Largest holders of MAIA from 13D and 13G filings
HolderLatest formStakeChangeFirst filedLatest filingFiling
FGMK Business Holdings, LLC13G9.99%2.89M sharesNewMar 3, 20251 filingMar 3, 2025SEC
Vitoc Vlad13D/A9.66%3.85M shares–Feb 14, 20233 filingsDec 4, 2025SEC